Fig. 5: Lomitapide suppresses the growth of patient-derived CRC organoids. | Cell Death & Disease

Fig. 5: Lomitapide suppresses the growth of patient-derived CRC organoids.

From: Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR

Fig. 5

a Dose-response curves of patient-derived CRC organoids CRC-01 (KRASWT; APC and TP53 mutant) and CRC-02 (KRASG12V; APC and TP53 mutant) treated with 10 μM 5-FU or 10 μM lomitapide. The organoid size was measured and quantified at 48 h of either 5-FU or lomitapide treatment relative to vehicle control. b Dose-response images of patient-derived CRC organoids CRC-01 and CRC-02 treated with DMSO, lomitapide, or 5-FU for 72 h at indicated concentrations. Organoids were stained with CFSE as an organoid marker (blue) and PI as a dead cell marker (red). Scale bars: 2 mm for CRC-01 and 1 mm for CRC-02. c H&E staining of the original matrigel CRC-01 organoid culture. Scale bar: 1 mm. d LC3 levels were measured by immunoblotting to assess autophagy induction. Lysates were prepared from organoids treated with vehicle, 10 μM lomitapide, or 10 μM 5-FU for 48 h.

Back to article page